PURPOSE: To provide the titled inhibiting agent containing a 1,5-benzothiazepine derivative or its acid addition salt as an active component.
CONSTITUTION: The objective blood platelet coagulation inhibiting agent can be produced by using the compound of formula I (R1 is lower alkyl; R2 is H or lower alkanoyl; R3 is lower alkyl) or its acid addition salt as an active component. The agent is effective to remedy, alleviate and prevent the diseases such as cerebral infarction, cerebral thrombosis, transient cerebral ischemia, myocardial infarction, etc. It can be administered orally or parenterally in the form of a solid agent such as tablet, capsule, suppository, etc., or a liquid such as solution, emulsion, etc. Dose: preferably 0.05W50mg/kg daily for oral administration and 0.05W10mg/kg for parenteral administration. The compound of formula I used as an active component can be produced e.g. by reacting the compound of formula II with the compound of formula III (Q is protecting group; X is halogen) and removing the protecting group from the resultant compound of formula IV.
OISHI ATSUO
NAKAJIMA HIROMICHI
NAGAO HIROSHI
